Abstract
Meigs syndrome is defined as the co-existence of benign ovarian tumor with ascites and hydrothorax that resolves after resection of tumor. The ovarian tumor in Meigs syndrome is fibroma. On the contrary, Pseudo- Meigs syndrome is characterized by the co-existence of hydrothorax, ascites and ovarian tumor either benign or malignant other than ovarian fibroma. The case herein concerns a 70 year old postmenopausal woman presented with the complaints of progressive shortness of breath on exertion and progressive swelling of lower abdomen. Her clinical and radiological examination revealed a massive right sided pleural effusion, mild ascites and a large heterogeneous pelvic mass with solid and cystic components, suggestive of left ovarian tumor. The patient underwent an exploratory laparotomy with excision of tumor, right ovary and whole of the uterus. The tumor was diagnosed histologically as an ovarian mucinous ystadenoma. Postoperative resolution of hydrothorax and ascites confirmed the diagnosis of Pseudo-Meigs syndrome. DOI: http://dx.doi.org/10.3329/jom.v13i2.12760 J Medicine 2012; 13 : 216-218
Highlights
The co-existence of pelvic tumor, hydrothorax and ascites has been known since the late 19th century
Pseudo-Meigs syndrome is characterized by the coexistence of hydrothorax, ascites and other ovarian- usually malignant or pelvic tumors
Three months later a follow up chest x-ray and ultrasonogram showed resolution of hydrothorax and ascites confirmed the diagnosis of Pseudo-Meigs syndrome (Fig.-2)
Summary
The co-existence of pelvic tumor, hydrothorax and ascites has been known since the late 19th century. Pseudo-Meigs syndrome is characterized by the coexistence of hydrothorax, ascites and other ovarian- usually malignant or pelvic tumors. Ultrasonogram of abdomen demonstrated mild ascites and a large heterogeneous, with solid and cystic components, pelvic tumor measured (20cmX15cm) suggestive of left ovarian mass. These findings were combined with mild anaemia (Hb. Conc: 10.5 gm/dl), high ESR (50 mm in 1st hour), serum CA-125 (32.08 U/ml, NR:
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
